Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Accured Expenses (2019 - 2025)

C4 Therapeutics' Change in Accured Expenses history spans 7 years, with the latest figure at $2.1 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses fell 47.95% year-over-year to $2.1 million; the TTM value through Dec 2025 reached -$6.0 million, down 377.43%, while the annual FY2025 figure was -$6.0 million, 377.43% down from the prior year.
  • Change in Accured Expenses reached $2.1 million in Q4 2025 per CCCC's latest filing, up from -$2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $5.2 million in Q4 2023 to a low of -$7.7 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $173000.0, with a median of $1.3 million recorded in 2021.
  • The largest YoY upside for Change in Accured Expenses was 669.17% in 2024 against a maximum downside of 426.07% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at $2.1 million in 2021, then increased by 26.09% to $2.7 million in 2022, then soared by 92.5% to $5.2 million in 2023, then dropped by 23.29% to $4.0 million in 2024, then plummeted by 47.95% to $2.1 million in 2025.
  • Per Business Quant, the three most recent readings for CCCC's Change in Accured Expenses are $2.1 million (Q4 2025), -$2.0 million (Q3 2025), and $627000.0 (Q2 2025).